Clinical trials: psoriasis
Severe Plaque Type Psoriasis
Quality of Life of Patients With Psoriasis Treated With Methotrexate: Prospective, Randomized, Double-blind, Parallel Group Study.
Methotrexate (MTX) is considered the 'gold-standard' drug for the treatment of severe psoriasis. Health-related quality of life (HRQOL) is impaired in patients with psoriasis, more so if disease is severe.
- Trial name
- NCT02248792
- Testing
- Methotrexate
- Where
- India
- Volunteers
- 50 people
- Sponsor
- Narayana Medical College & Hospital
Plaque Psoriasis
Safety and Efficacy Study Comparing AM001 Cream, 7.5% to Vehicle Cream in the Treatment of Plaque Psoriasis
To compare the safety and efficacy profiles of AM001 Cream, 7.5% and its vehicle cream in the treatment of plaque psoriasis
- Trial name
- NCT03005964
- Testing
- AM001 Cream, 7.5%, Vehicle Cream
- Where
- 2 sites in Dominican Republic
- Volunteers
- 74 people
- Sponsor
- AmDerma
Psoriasis
Desoximetasone Spray 0.05%, 0.25%; Dose Ranging Study
The objectives of this study are to evaluate the efficacy and safety of two dosing regimens of desoximetasone 0.05% and 0.25% topical sprays as compared to a vehicle spray in patients with moderate to severe plaque psoriasis.
- Trial name
- NCT01018134
- Testing
- Desoximetasone 0.05% once daily, Desoximetasone 0.05% twice daily, Desoximetasone 0.25% once daily
- Where
- 7 sites in United States
- Volunteers
- 151 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Psoriasis
A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
The primary objectives of the study are to 1) compare the efficacy responses of CP 690,550 (5 mg BID and 10 mg BID) versus placebo following 24 weeks of CP 690,550 treatment and subsequent withdrawal of active treatment at…
- Trial name
- NCT01186744
- Testing
- CP-690,550
- Where
- 87 sites in United States, Argentina and 10 more
- Volunteers
- 666 people
- Sponsor
- Pfizer
Plaque Psoriasis, Skin Diseases, Papulosquamous
Study Comparing AM001 Cream to Vehicle in the Treatment of Plaque Psoriasis
To compare the safety and efficacy profile of AM001 Cream and its vehicle in the treatment of plaque psoriasis.
- Conditions
- Plaque Psoriasis, Skin Diseases, Papulosquamous, Skin Diseases
- Trial name
- NCT01938599
- Testing
- AM001 Cream, 7.5%
- Where
- 5 sites in United States
- Volunteers
- 92 people
- Sponsor
- AmDerma
HIV Infections, Primary Health Care
HIV Indicator Diseases in Hospital and Primary Care
Patients are frequently evaluated by physicians for medical work-up of HIV indicator conditions in hospital and in primary care at the general practitioner.
- Conditions
- HIV Infections, Primary Health Care, Acquired Immunodeficiency Syndrome, Sexually Transmitted Diseases, Viral
- Trial name
- #AwareHIV (NCT05225493)
- Testing
- Peer to peer feedback, HIV rapid test
- Where
- Netherlands
- Volunteers
- 1,500 people
- Sponsor
- Erasmus Medical Center
Psoriasis (PsO)
Global Healthcare Study on Psoriasis
The Global Healthcare Study on Psoriasis (GHSP) is an international, multicenter observational study hosted by the University of Zurich (UZH) investigating healthcare access, treatment patterns, disease severity, and quality of…
- Trial name
- GHSP (NCT07634016)
- Where
- Switzerland
- Volunteers
- 9,600 people
- Sponsor
- Julia Tatjana Maul
Psoriasis, Vitamin D Deficiency
The Effect of Vitamin D Supplementation on Psoriasis Severity
The study evaluates the effect of oral vitamin D supplementation on the severity of psoriasis measured by Psoriasis Area Severity Index (PASI) in adults with lower vitamin D levels.
- Trial name
- NCT03334136
- Testing
- 25-Hydroxyvitamin D
- Where
- Norway
- Volunteers
- 115 people
- Sponsor
- University Hospital of North Norway
Psoriatic Arthritis
Effectiveness of Treatment With Tofacitinib in Patients With Psoriatic Arthritis in Routine Clinical Practice
This is a Multinational Study of Tofacitinib in Patients Treated for Psoriatic Arthritis in order to evaluate the effectiveness of treatment with tofacitinib on disease activity, remission, and Quality of Life, in a real-world…
- Trial name
- NCT04517669
- Where
- 41 sites in Belgium, Denmark and 6 more
- Volunteers
- 116 people
- Sponsor
- Pfizer
Psoriasis
BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
The purpose of this study is to assess the safety and efficacy of BI 655066/ABBV-066 (risankizumab) for the treatment of moderate to severe chronic plaque psoriasis in adult patients.
- Trial name
- NCT02684370
- Testing
- risankizumab, ustekinumab
- Volunteers
- 560 people
- Sponsor
- AbbVie
Psoriatic Arthritis
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO).
- Trial name
- NCT06671483
- Testing
- Zasocitinib, Active Comparator
- Where
- 188 sites in United States, Belgium and 18 more
- Volunteers
- 1,088 people
- Sponsor
- Takeda
Psoriasis
Efficacy and Safety of Acitretin Plus Pioglitazone in Patients With Psoriasis
Acitretin, when given in combiantion with pioglitazone might achieve better and/or more rapid control of moderate to severe chronic plaque type psoriasis.
- Trial name
- NCT00395941
- Testing
- Pioglitazone, Acitretin
- Where
- India
- Volunteers
- 40 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Psoriasis Vulgaris, Atopic Dermatitis
The Role Of Neutrophil Proteases As Global Regulators Of Il-1 Family Cytokine Activity In Skin Disorders
Pro-inflammatory cytokines are critically important drivers of inflammatory and autoimmune diseases and cytokine-targeted biologics have been transformative in the treatment of several inflammatory and autoimmune diseases.
- Conditions
- Psoriasis Vulgaris, Atopic Dermatitis, Ichthyosis Vulgaris
- Trial name
- NEUTROPRO (NCT04750161)
- Testing
- No intervention
- Where
- Ireland
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- St. James's Hospital, Ireland
Psoriasis Vulgaris
Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Ointment in Patients With Psoriasis Vulgaris
This study will evaluate the efficacy and safety of calcipotriol plus betamethasone dipropionate ointment compared with calcipotriol ointment in the treatment of patients with psoriasis vulgaris for a duration of 4 weeks.
- Trial name
- NCT00248456
- Testing
- Calcipotriol plus betamethasone dipropionate ointment
- Where
- China
- Volunteers
- 320 people
- Sponsor
- LEO Pharma
Rheumatoid Diseases, Rheumatoid Arthritis
Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Rheumatoid Diseases Who Are Naïve To Biologics Or Switched From Remicade
To assess persistence of CT-P13 in patients with Rheumatoid Diseases (Rheumatoid arthritis [RA], ankylosing spondylitis [AS], and psoriatic arthritis [PsA]) who are naïve to biologics or are switching from stable Remicade to…
- Conditions
- Rheumatoid Diseases, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
- Trial name
- PERSIST (NCT02605642)
- Testing
- CT-P13
- Where
- 38 sites in Bulgaria, Canada and 5 more
- Volunteers
- 351 people
- Sponsor
- Pfizer
Chronic Plaque Psoriasis
Efficacy and Safety of Cyclosporine A Microemulsion in Maintenance Patients With Chronic Plaque Psoriasis
The study will evaluate the efficacy of cyclosporine at 2, 5 mg/kg/day bid (i.e. bis in a day), when administered twice a week compared to continuous administration, in patients with chronic plaque psoriasis.
- Trial name
- NCT00438360
- Testing
- Cyclosporine A microemulsion
- Where
- Italy
- Volunteers
- 243 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque Psoriasis
Hemay005 is a novel phosphodiesterase type 4(PDE4) inhibitor being developed for the treatment of psoriasis.After single asending dose and mutiple asending dose in health subjects.
- Trial name
- NCT04102241
- Testing
- 15mg Hemay005
- Where
- China
- Volunteers
- 216 people
- Sponsor
- Tianjin Hemay Pharmaceutical Co., Ltd
Autoimmune Bullous Dermatosis, Dysimmune Dermatological Diseases
Clinico-biological Collection of Autoimmune, Dysimmune or Auto-inflammatory Dermatological Diseases
The aim of this project is to start a biological and clinical collection of patients presenting autoimmune, dysimmune or auto-inflammatory dermatological diseases.
- Conditions
- Autoimmune Bullous Dermatosis, Dysimmune Dermatological Diseases, Auto-inflammatory Dermatological Diseases, Skin Diseases
- Trial name
- TekAPo (NCT06387654)
- Testing
- Blood sampling, Remainders of samples taken as part of the treatment
- Where
- France
- Volunteers
- 800 people
- Sponsor
- University Hospital, Toulouse
Psoriasis
A Study of Guselkumab (TREMFYA) in Chinese Participants With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the efficacy, safety and tolerability of guselkumab in the treatment of Chinese participants with moderate to severe plaque psoriasis.
- Trial name
- NCT04914429
- Testing
- Guselkumab
- Where
- 26 sites in China
- Volunteers
- 327 people
- Sponsor
- Janssen Research & Development, LLC
Scalp Psoriasis
Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product
An Open-Label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use DSXS topical product (Taro Pharmaceuticals U.S.A., Inc.) in Patients with Moderate to SevereScalp Psoriasis
- Trial name
- NCT02933502
- Testing
- DSXS topical product
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.